The proposal is straightforward: Move toward biomarker-driven patient stratification Design more flexible, biology-informed clinical trials Align regulatory approaches with what already works in oncology and dementia Dementia offers a useful reference point
Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality
Progress in this area has been hindered by the limitations of rodent models (even with human microbiota implantation), which fail to fully replicate the complexity of the human gut-liver axis
Importantly, with continued treatment, some patients may experience a lessening of the gastric-emptying effects while the central appetite-suppressing effects often persist
Third, pace your weight loss to no more than 1-2 pounds per week
This is the second head-to-head study after Eli Lilly registered its intent to carry out a Phase 3b clinical trial in April 2023 that will see the companys tirzepatide (Mounjaro) compared with Novo Nordisks semaglutide (Wegovy) 2.4mg in 700 adult participants who have obesity or overweight with weight related comorbidities without Type 2 diabetes
